Antiphospholipid antibodies in neurology in 2008: difficulties for guidelines
Radu Tanasescu
Romanian Journal of Neurology · 2009
doi:10.37897/rjn.2009.1.1 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Antiphospholipid antibodies (APL) and neurological diseases are a subject of great interest in the last 20 years, but also a field of controversy. Several consensus meetings have raised expert points of view, and some studies provided evidence-based data, however, a guideline for the management of neurological manifestations associated to APL is difficult to be generated. Some of the controversy points and difficulty in ordering rules for practice are debated.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.